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ABSTRACT  
Infection of hepatitis B virus (HBV) is a global health 
problem, including in Indonesia. There are currently an estimated 
2 billion people worldwide are infected with HBV, about 75% of 
them are in Asia and 350 million of them will develop into chronic 
hepatitis B. Factors that influence the development of chronic 
hepatitis B into liver carcinoma include x gene mutation, HBV 
genotype and subgenotype. This research aims to identify x gene 
mutation, genotype and subgenotype of HBV infecting hepatitis B 
patients in Manado associated with the onset of liver carcinoma. 
HBV DNAs were isolated from blood samples of 30 hepatitis B 
patients. X gen was amplified using nested PCR with pre-
designed primer pairs. Amplified DNA fragments were 
electrophoresed in 1.5% agarose and visualized under UV. DNA 
fragments were then separated and purified using Qiagen 
column, then sequenced to determine their nucleotide sequences 
of x gene. Amino acid of x protein were deduced from nucleotide 
sequence of x gene and used as basic to determine HBV 
genotype and subgenotype. X protein was aligned with those 
similar protein with the same subgenotype retrieved from 
GenBank to determine if there was a mutation at amino acid.  
The mutated x protein were compared with other mutation found 
in x protein in other literatures associated with the onset of liver 
carcinoma. Genotype and subgenotype of HBV isolated from 
blood samples of 10 patients was detected and showed that five 
patients were infected with B genotype HBV (2 patients were 
infected with B2 subgenotype, 2 patients with B3 subgenotype 
and 1 patient with B9 subgenotype). The rest of 5 patients were 
infected with C genotype HBV (1 patient with C1 subgenotype, 2 
patients with C2 subgenotype,  and 2 patients with C5 
subgenotype). The mutation in x protein is related significantly to 
the clinical severity of the liver and hepatocellular  carcinoma 
(HCC), ie V5L in subgenotype C2, and I127T and H94Y in 
subgenotype C5. 
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INTRODUCTION 
Hepatitis B infection is caused by the 
hepatitis B virus (HBV). This disease can cause 
acute and chronic hepatitis B. Chronic hepatitis 
B may progress to liver cirrhosis and liver 
carcinoma (hepatocellular carcinoma, HCC). 
With more than 500,000 events predicted in 
2000, HCC is the most frequent malignant 
tumor in the world and the rate of incidence is 
increasing in many countries including 
Indonesia. Although it is the most common 
cancer found in patients, with rank fifth for the 
amount, HCC is the third leading cause of 
death after lung and stomach cancer 
(Lupberger and Hildt, 2007). 
Hepatitis B virus is a part of the 
Hepadnaviridae family of viruses. This virus 
consists of nucleocapsid and external envelope 
that mainly harbors three surface antigens 
HBsAg that play a role in the diagnosis of HBV 
infection. Its nucleocapsid contains core 
antigen of hepatitis B (HBcAg), reverse 
transcriptase, viral genome, and cell protein. 
The genome consists of circular DNA molecule 
with the size of 3200 bp. S gene  encodes for 
three antigens namely pre-S1, pre-S2, and S, 
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which are the variation of HBsAg. Proteins 
encoded by pre-core (pre-C)/core (C) genes 
undergo post-translational modification to 
produce Be antigen (HBeAg), which is a 
seromarker for high levels of viral replication. 
Core gene encodes for HBcAg, a major 
structural protein of nucleocapsid. X gene  
encodes for hepatitis B x antigen  (HBxAg) 
which is known as powerful cell transactivator 
and viral gene. Several interactions with cell 
proteins have been proposed as HBxAg target 
(Baumert et al., 2007).  
Research on HCC has a lot of concern 
especially in relation to risk factors both in 
terms of the virus and its host. Several studies 
have identified factors associated with HBV as 
a predictor of the emergence of HCC in 
patients with chronic hepatitis B. An example is 
seropositivity HBeAg. High content of virus 
and HBV genotype C are interrelated 
predictors for HCC. In addition, HBV DNA 
content is also correlated with the risk of 
cirrhosis development. These factors are 
interrelated, for example, patients with 
genotype C is more often had HBeAg-positive 
compared with patients with genotype B. 
Another genetic character also recently been 
identified. Precore and basal core promoter 
(BCP) mutant are the most common in HBV 
mutants. Double mutations in BCP 
A1762T/G1764A have been reported related 
to development of HCC (Lupberger and Hildt, 
2007). The area which control the transcription 
of BCP and precore core region overlaps with a 
x gene. Mutations in the precore region 
prevents the synthesis of HBeAg, but still 
allows the formation of a virus. G1986A 
mutation causes a premature stop codon, and is 
commonly found in HBV that infects HBeAg-
negative patients and some fulminant hepatitis 
B. Double mutation A1762T/G1764A decrease 
the expression of HBeAg but increase the 
replication of HBV genome (Yang et al. 2008). 
One study showed that the incidence of HCC 
was higher in genotype C than genotype B, with 
variant precore G1896 (wild-type) higher than 
G1896A variant, and the BCP double mutation 
A1762T/G1764A is significantly higher 
compared with the wild-type variant of the 
BCP. The highest risk occurs when infected 
with HBV genotype C and the wild-type variant 
for the precore 1896, and mutant for BCP 
variants A1762T/G1764A (Yang et al., 2008). 
Mutations of PreS VHB C1653T, T1753V, and 
A1762T/G1764A have been reported to have 
risk factors associated with HCC in a meta-
analysis. These mutations are considered as a 
mechanism to avoid themselves from host 
immune system and can affect the potential 
inchogenic chronic hepatitis B disease. 
HBV x gene is the gene with the smallest 
size, but encodes a multifunctional protein of 
154 amino acids, with amino end containing 
antiapoptotic domain/negative regulation, and 
carboxyl end containing proapoptotic/ 
transactivation. This gene also appears to be 
associated with the modulation of various cell 
functions that cause HCC. One study showed 
that mutations that occur in HBx131, HBx130, 
HBx5, HBx94, and HBx38 were commonly 
found in patients with HCC. Of these 
mutations, double mutation (HBx130/HBx131) 
and triple mutation HBx5/HBx130/HBx131 
were very significantly found in HCC patients. 
A double and a triple mutation increase the risk 
of HCC, with 3.75 times and 5.34 times 
respectively. HBx5 mutation in HBV genotype 
C2 appears to be a risk factor for development 
of HCC and can be used to predict the clinical 
impact of chronic HBV infection (Lee et al. 
2011).  
Frequency of  x protein  mutation in 
patients with more severe hepatitis B, 
hepatocellular carcinoma (3.6%) or liver 
cirrhosis (4%) was always significantly higher 
than patients with less severe forms, chronic 
hepatitis (2.9%) or career asymptomatic (2.1%), 
but there was no significant difference in 
serological status for HBeAg. The six 
mutations ((V5M/L, P38S, H94Y, I127T/N, 
and K130M and V131I) affect the six codons, 
which are known significantly associated with 
clinical severity. Among these mutations, two 
types of mutations (V5M / L and K130M and 
V131I) were found more frequently in patients 
with HBeAg negative than patients with 
HBeAg positive. 
This study concludes that there is 
accumulation of mutations in the x gene, which 
contribute to the progress of the disease in 
patients with chronic hepatitis, at least in 
patients in Korea with genotype C. Particular 
type of mutation appears to be associated with 
severe hepatitis such as HCC or liver cirrhosis. 
Identification of X Gene  Mutations 
Volume 25 Issue 4 (2014) 272 
Type a new mutation (V5M / L) was found to 
correlate with HCC. This study also shows that 
the rate of mutations in x gene  is associated 
with the emergence of HCC. Mutation rate             
in patients with HCC was 3.6%, liver cirrhosis 
(4%), chronic hepatitis (2.9%), and only            
2.1% in asymptomatic career (Kim et al.,          
2008).  
Because information about mutations in 
x gene, genotype and subgenotype of HBV that 
infect patients with hepatitis B is very 
important to , the study aims to identify x gene 
(x protein) mutation, genotype and 
subgenotype of HBV infecting hepatitis B of 
some patients in Manado associated with the 
onset of liver carcinoma.  
 
MATERIALS AND METHODS 
Materials 
Sterile aquadest , primer HBV_1233_for 
5’-CATGCGTGGR (A/G)ACCTTTGTG-3’, 
primer HBVF1_1685_rev 5’-GCCTCAAG 
GTCGGTCGTT-3’, primer HBVF2_1545_for 
5’-CTCCCC GTCTGTGCCTTC-3’ (1st Base), 
primer HBVF2_1940_rev 5’-CAGAAGGCAA 
AAAAGAGA GTAACTC-3’ (IDT), MgCl2 
(MD Bio), Taq pol (MD Bio), buffer 10x (MD 
Bio), dNTP 10mM (Vivantis), DMSO,  marker 
DNA 100 bp (MD Bio), marker DNA 1kb 
(Fermentas), agarose (Promega), glacial            
acetic acid (Merck), Tris Base (J. T. Barker), 
EDTA (J. T. Barker), and ethidium bromide 
(Promega). 
 
Equipments 
Applied biosystem 2720 Thermal Cycler, 
autoclave (All American Model 25x America), 
elektrophoreses gel (BioRad), microwave 
(Goldstar), micropippete (Eppendorf), 
measuring glass (Pyrex), Erlenmeyer flask 
(Herma, Pyrex), micropippete tip (Biologix), 
microtube (Biologix), and digital camera 
(Canon). 
 
Sample Preparation 
A total of 2mL of blood serum sample 
of 30 patients infected with hepatitis B were 
taken and put into EDTA tubes and stored at 
4°C prior to the isolation of HBV DNA. 
Collected  in  January until June 2013 , 
consisting of 15 people each women and men , 
with age 40-60 years. 
Isolation of VHB DNA 
Isolation of HBV DNA was performed 
in the Clinical Laboratory Pramita Jakarta. The 
DNA was isolated from patients’ serum using 
High Pure Viral nucleic acid kit (Roche). Virus 
is lysed by incubating in buffer lysis with 
proteinase K. Free nucleic acid is bound 
specifically to the surface of glass fiber with 
Chaotropic salts. DNA is then washed to 
remove other impurities and then eluted with a 
low power salt buffer or water. 
 
Amplification of x gene and 
electrophoreses  
Nested PCR was performed on a total of 
30 isolates DNA from serum samples that had 
been isolated in the Clinical Laboratory Pramita 
Jakarta. The composition of the first phase of 
the PCR mixture was : sterile aquadest 17.75µL, 
buffer 2.5µL, MgCl2 2µL, dNTP 0.5µl, Primer 
For 5’-CATGCGTGGR(A/G)ACCTTTGTG-
3’  (20mM) 05µL, Primer Rev (20mM) 0.5µL,  
Taq pol 0.25µL, and 1.0 µL DNA template. The 
first PCR conditions were as follows: initial 
denaturation at 94°C for 5min; denaturation at 
94°C for 30sec, annealing at 50°C for 1min, 
extention at 72°C for 1min, repeated as many 
as 25 cycles; and ended with final extention at 
72°C for 10min. The results of the first PCR 
was diluted 10x, 25x and 100x times and 1μL 
then was taken to be a template in the second 
PCR. The PCR mixture and condition were the 
same with the first PCR with different primers, 
namely HBV_1233_For and  
HBVF1_1685_rev to get the first x gene 
product fragment, and HBVF2_1545_for  and 
HBVF2_1940_rev to get the second x gene 
product fragment. PCR products were 
electophoresed in 1.5% agarose gel and 
visualized under UV. 
 
Nucleotide Sequence Determination of 
HBV x Gene  
PCR products were purified from 
agarose gel by cutting the gel, then purified 
using Qiagen columns. The nucleotide 
sequences of the PCR products are determined 
both directions using the primers used in the 
second PCR using the authomatic dideoxy 
method. Determination of the nucleotide 
sequence of PCR products was performed at 
Macrogen Inc. (South Korea) 
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Determination of HBV genotypes and 
subgenotype of patients with hepatitis 
B 
Nucleotide sequence obtained was used 
as the basis for determining the genotype and 
subgenotype of hepatitis B virus. Amino acid 
sequenced was deduced from nucleotide 
sequence for amino acid-based analysis. 
Percentage homology to the nucleotide 
sequence / amino acid sequences deposited in 
GenBank 
(http://www.ncbi.nlm.nih.goc/genbank) and di 
EMBL (http://www.ebi.ac.uk) was calculated. 
Phylogeny analysis was also performed to 
determine the genotype of hepatitis B virus by 
first using a multiple alignment program at EBI 
Clustaw 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) 
and Clustaw2 (http://www.ebi.ac.uk/Tools/ 
phylogeny/).  Closest evolutionary distance to 
the sequence deposited in GenBank Data will 
be understood from this analysis. 
 
Mutation Detection 
The presence of mutation was detected 
by aligning the nucleotide sequence and amino 
acid sequence with its wildtype counterpart 
using ClustalW. Sequence of VHB wildtype 
subgenotype was retrieved from GenBank 
(NCBI). 
 
RESULTS AND DISCUSSION 
Amplification of X gen HBV dan 
Elektroforesis 
Nested PCR was conducted with two-
stage PCR. The first PCR was aimed at 
obtaining intact x gene and its surrounding with 
theoretical PCR product of 707 bp (Vincent, 
2010). The second round PCR was done to 
obtain x gene fragment with theoretical first 
PCR product of 469 bp and second PCR 
product of 395 bp (Rini, 2013). Agarose gel 
electrophoreses showed that PCR product in 
optimum condition with annealing temperature 
500C and 100x dilution for samples F3, F4, F5, 
F7, F10, and F28, 25x dilution for samples F17 
and F18, and 10x dilution for samples F8 and 
F9. First fragment of 480 bp and second 
fragment of 400 bp were obtained as shown in 
Figure 1.  
 
 
 
 
Figure 1. Electroferogram of PCR products of 
both x gene with 100x dilution. M = DNA 
marker, 1 = first fragment from sample F3, 2 = 
second fragment from sample F3, 3 = first 
fragment from sample F4, 4 = second fragment 
from F4, 5 = first fragment from sample F7, 6 
= second fragment from sample F7. 
 
X gene of 10 samples were successfully 
to amplified while the other samples were not 
successfully even have repeatedly done 
optimization , this is because the quality of the 
serum samples were not good and likely due to 
the length of time of storage of the samples 
prior to DNA isolation.  
 
BLAST Analysis 
Determination of nucleotide sequence 
was done in one direction using primer 
HBV_1233_For for first fragment sample and 
HBVF2_1545_For for second fragment 
sample. Nucleotide sequence for both 
fragments were analysed for each sample and 
contig was performed to obtain intact x gene . 
Amino acid sequence was translated based on 
intact x gene  nucleotide sequence to obtain x 
protein. Blast analysis was conducted to obtain 
the degree of homology with x protein of HBV 
obtained from GenBank.  
Having ascertained that the x gene of 
hepatitis B is amplified, ined. Blast analysis 
showed that amino acid sequences obtained 
from the 10 samples are x protein of hepatitis B 
virus. Blast analysis for saits genotype and 
subgenotype were determmple F4 can be seen 
in Figure 2. 
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The blast analysis of x protein result 
showed that 5 samples are HBV with genotype 
B, with following details: 1 sample was B1 
subgenotype and 4 samples were B2 
subgenotype. Five samples are amongst 
genotype C with following details: 2 samples 
were subgenotype C1, 1 sampel was 
subgenotype C2, and 2 samples were 
subgenotype C5. Blast analysis for all samples is 
shown in table I. 
 
Mutation Analysis   
Amino acid sequence of HBV x protein  
was aligned with their counterpart to detect any 
mutation in its gene. Alignment result of 
sample F10 with its HBV wildtype subgenotype 
C2 is shown in Figure 3. The same workflow 
was performed on all amino acid sequences, in 
order to obtain genotype, subgenotype, and 
mutation data in each sample, as shown in table 
I. 
Some mutations have been found on 
HBV samples. The mutations found, however, 
most of them have never been confirmed about 
its relation to the increased risk of liver cancer. 
Mutation of each sample is shown at table I. 
Red writings are mutation related to clinical 
severity of the liver and liver carcinoma. 
Referring to the genotype of hepatitis B 
virus infecting patients, the same number of 
patients infected with HBV genotype B and C 
shows that prevalence of genotype C (50%) is 
 
 
Figure 2. Blast analysis of amino acid sequence of  x protein Isolate F4 homology with x protein of 
HBV in GenBank. 
 
                         
 
Figure 3. Alignment result of isolate F10 using Clustal W2. 
 
Table I. Analysis of HBV genotype/subgenotype and protein x mutation 
 
No Sampel Code Genotype/ subgenotype Protein x mutation 
1. F3 B/B2 R87G, E119A, W120E 
2. F4 B/B2 V45I, P46Q,R87G, N149T 
3. F5 B/B2 V44A 
4. F7 C/C5 G22S, S111P, I127T 
5. F8 B/B1 L37I,T118N, A145T 
6. F9 B/B2 V45L 
7. F10 C/C2 V5L, S43P, H52N, H86R, L116V 
8. F17 C/C1 V30I, V131T 
9. F18 C/C5 H94Y 
10. F28 C/C1 T36P, A44T 
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high enough, not much different from that 
found by Mulyanto et al. (2009) that 10 out of 
14 patients infected by HBV, were infected 
with genotype C. Wang et al. (2012) showed 
that infection of genotype C relatively more 
frequent causing cirrhosis and liver cancer 
compared with genotype B. 
Genotypic differences also make a 
difference in response to treatment with IFN-α, 
in which genotype B has a better response to 
treatment using IFN-α compared to genotype 
C  (Kao et al., 2000; Wai et al., 2007). The same 
also happens to antiviral treatment with 
lamivudine, although both types of these 
genotypes have a risk of mutations that cause 
drug resistance after administration of 
treatment more than 1 year (Kao et al., 2002). 
Thus, the type of HBV genotypes which infects 
patient needs to be known, as early information 
on clinical investigation. 
This study showed that all HBV-infected 
patients had mutations in the protein x. Protein 
x HBV is associated with the pathogenesis of 
HBV related diseases, especially in 
hepatocellular carcinomas of chronic patiens. 
Cohort study showed that mutation of amino 
acid at position 127, 130 and 131 were 
associated with liver disease (Barbini et al., 
2012). Five types of mutation, i.e V5M/L, 
P38S, H94Y, I127T/N, dan K130M and V131I 
which affecting the six codons were found to 
be related significantly to clinical severity. 
Among these mutations, three types of 
mutation namely V5M/L, K130M and V131I 
were frequently found in patients with negative 
HBeAG compared to those with positive 
HBeAD (Kim et al., 2008). Eventhough double 
or triple mutations were not found in this 
study, however 3 patients with HBV mutations 
were linked with an increased risk of liver 
cancer, namely V5L in subgenotype C2, and 
H94Y and I127T in subgenotype C5. Mutation 
V5L in subtype C2 was significantly associated 
with HCC (Kim et al., 2008). Genotype C2 is a 
factor, which was independently linked to an 
increased risk of liver cancer (Cao et al., 2008). 
Considering most chronically infected patients 
did not show any symptoms until eventually 
developed cirrhosis or liver carcinoma (Hann et 
al., 2007), then the early detection of the 
genotype / subgenotype and  x gene / x 
protein  mutations needs to be done. 
CONCLUSION 
Genotype and subgenotype of HBV 
isolated from blood samples of  10 HBV 
infecting hepatitis B patients was detected and 
showed that five patients were infected with B 
genotype HBV (2 patients were infected with 
B2 subgenotype, 2 patients with B3 
subgenotype and 1 patient with B9 
subgenotype). The rest of 5 patients were 
infected with C genotype HBV (1 patient with 
C1 subgenotype, 2 patients with C2 
subgenotype,  and 2 patients with C5 
subgenotype). The mutation in x protein is 
related significantly to the clinical severity of 
the liver and hepatocellular  carcinoma (HCC), 
ie V5L in subgenotype C2, and I127T and 
H94Y in subgenotype C5. 
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